Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价4价流感病毒裂解疫苗在3岁及以上人群中接种的安全性和免疫原性的随机、盲法、阳性对照III期临床试验
[Translation] A randomized, blinded, positive-controlled phase III clinical trial to evaluate the safety and immunogenicity of a 4-valent influenza virus split vaccine in people aged 3 years and above
评价4价流感病毒裂解疫苗在3岁及以上人群中接种的安全性和免疫原性。
[Translation] To evaluate the safety and immunogenicity of 4-valent influenza virus split vaccine in people aged 3 years and above.
评价4价流感病毒裂解疫苗用于6~35月龄、3岁及以上健康人群安全性的开放式Ⅰ期临床试验
[Translation] An open phase I clinical trial to evaluate the safety of a quadrivalent influenza virus split vaccine in healthy people aged 6 to 35 months and 3 years and above
评价4价流感病毒裂解疫苗在6~35月龄、3岁及以上健康人群中接种的安全性
[Translation] To evaluate the safety of quadrivalent influenza virus split vaccine in healthy people aged 6 to 35 months and 3 years and above
100 Clinical Results associated with Jiangsu Walvax Biotechnology Co., Ltd.
0 Patents (Medical) associated with Jiangsu Walvax Biotechnology Co., Ltd.
100 Deals associated with Jiangsu Walvax Biotechnology Co., Ltd.
100 Translational Medicine associated with Jiangsu Walvax Biotechnology Co., Ltd.